A 24-Month Phase 3 Multicenter Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer's Disease Protocol# H8A-MC-LZBE
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to evaluate whether solanezumab can slow the progression of early Alzheimer?s disease.\
Description
The purpose of this study is to see whether solanezumab can slow the progression of prodromal Alzheimer's disease.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 55 Years - 85 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 1604616382
